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Background Vast sample sizes are often essential in the quest to disentangle the
complex interplay of the genetic, lifestyle, environmental and social
factors that determine the aetiology and progression of chronic dis-
eases. The pooling of information between studies is therefore of
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1383central importance to contemporary bioscience. However, there are
many technical, ethico-legal and scientific challenges to be over-
come if an effective, valid, pooled analysis is to be achieved.
Perhaps most critically, any data that are to be analysed in this
way must be adequately ‘harmonized’. This implies that the collec-
tion and recording of information and data must be done in a
manner that is sufficiently similar in the different studies to
allow valid synthesis to take place.
Methods This conceptual article describes the origins, purpose and scientific
foundations of the DataSHaPER (DataSchema and Harmonization
Platform for Epidemiological Research; http://www.datashaper.org),
which has been created by a multidisciplinary consortium of experts
that was pulled together and coordinated by three international
organizations: P
3G (Public Population Project in Genomics),
PHOEBE (Promoting Harmonization of Epidemiological Biobanks
in Europe) and CPT (Canadian Partnership for Tomorrow Project).
Results The DataSHaPER provides a flexible, structured approach to the
harmonization and pooling of information between studies. Its
two primary components, the ‘DataSchema’ and ‘Harmonization
Platforms’, together support the preparation of effective
data-collection protocols and provide a central reference to facilitate
harmonization. The DataSHaPER supports both ‘prospective’ and
‘retrospective’ harmonization.
Conclusion It is hoped that this article will encourage readers to investigate the
project further: the more the research groups and studies are ac-
tively involved, the more effective the DataSHaPER programme will
ultimately be.
Keywords Data synthesis, data quality, data pooling, harmonization, meta-
analysis, DataSHaPER, prospective harmonization, retrospective
harmonization
Introduction
Scientific developments in the wake of the Human
Genome
1–3 and HapMap
4,5 projects are helping to
shape the future of public health and clinical medi-
cine.
6–8 However, while dramatic progress has been
made in detecting genetic associations with complex
diseases,
9,10 the role of genetic determinants is only a
part of a much larger picture. The role of lifestyle,
environmental and social factors in modulating the
risk and/or progression of chronic diseases has been
recognized and explored for many years.
11,12 This is
entirely logical even from the perspective of functional
genomics: the concept of ‘fitness’ that is central to
natural selection and human evolution has, as its fun-
damental basis, the interaction between prevailing en-
vironment and the genome.
13 This implies that causal
pathways leading to disease should be ‘expected’ to
involve gene–environment interactions.
14,15
It is therefore clear that bioscience needs access to
studies that incorporate social, environmental and
lifestyle factors as well as genetic determinants.
7,15
Provided that the quality of the information that
such studies generate is adequate and that the statis-
tical power of key analyses can be rendered suffi-
cient,
15–18 it will then be possible to successfully
pursue a comprehensive investigation of the direct
and interactive effects of a broader range of relevant
classes of aetiological determinants. However, in the
real world, the attainment of adequate statistical
power presents a serious challenge. For example,
when appropriate account is taken of assessment
errors in both determinants and outcomes,
sample-size estimates for analyses involving gene–
environment interactions comparable in magnitude
with the direct genetic effects that have so far been
replicated,
9,10,16 typically indicate a requirement for
‘tens of thousands of cases’.
16,17,19 This means that
even the largest
16,20–22 and best measured
18,23 of con-
temporary studies will only be able to generate
enough cases—or subjects—for the commonest of
complex diseases.
16,22 This in turn implies that the
analysis of synthesized data across several studies
is set to become increasingly important.
15,24
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scientific projects,
25–27 and to facilitate synthesis of
information among studies
28–34 or data portals.
35–39
Fortunately, extensive experience already exists in
the synthesis of epidemiological studies.
33,40–42 For
example, data synthesis was pivotal to the success
of the EPIC study (the European Prospective
Investigation into Cancer and Nutrition) which start-
ing in the 1990s, recruited more than 500000 partici-
pants via (initially) 22 centres across nine European
countries.
28,43 EPIC’s focus on nutrition placed heavy
demands on sample size, and effective data synthesis
across all centres was therefore critical to many of its
principal analyses. Although EPIC was designed pro-
spectively as a coordinated consortium of studies,
centre-specific questionnaires were used.
28,44 In such
a setting, the data synthesis was constrained by the
quality
18 of the underlying data and by their compati-
bility.
45 One of the important achievements of the
EPIC project was the development of methods and
tools (e.g. EPIC SOFT
43) to enable calibration and
pooling of data that had been collected under differ-
ent protocols in different centres, so that data synthe-
sis was rendered valid.
However, in common with other major epidemio-
logical consortia—e.g. GenomEUtwin project
30 and
EURALIM project
41—EPIC demonstrated that infor-
mation synthesis is far from easy. It demands time,
resources and rigour.
40,43,44,46 Furthermore, as scien-
tific ambitions and capacities have extended, the
sample-size challenge continues to grow,
9,15–18 and
the requirement for effective data synthesis has now
become a regular necessity.
15,24 Moreover, as different
sets of outcome and exposure variables are required
for different analyses—and no single study can afford
to capture ‘all’ desired measures—individual studies
are necessarily being pooled with different combin-
ations of other studies—as demonstrated, e.g. by the
number of different consortia involving studies such
as Avon Longitudinal Study of Parents and Children
(ALSPAC), EPIC-Norfolk and the 1958 Birth
Cohort.
25,26,47,48 This implies that it would be benefi-
cial to supplement consortium-specific approaches to
harmonization, calibration and synthesis
29,30,34,41,43
with more generic methods.
49–52
However, the scientific utility of data synthesis is
always constrained by the quantity and quality of
the underlying data,
18,53 and by their compatibility
between studies.
45,54 The latter implies that the col-
lection and recording of information and data must
be carried out in a manner that is sufficiently similar
in the different studies to allow valid synthesis to take
place. When this is so, ‘harmonization’ may be said to
exist.
53 The fundamental challenge might therefore be
viewed as being to increase sample size by synthesiz-
ing over an adequate number of studies, but to re-
strict that synthesis to those studies that are
satisfactorily harmonized for the specific outcomes,
genetic, environmental and lifestyle factors
targeted.
42,54 Two complementary approaches may
be adopted to support effective data synthesis. The
first one principally targets ‘what’ is to be synthesized,
whereas the other one focuses on ‘how’ to collect the
required information. Thus: (i) core sets of informa-
tion may be identified to serve as the foundation for a
flexible approach to harmonization
51,52,55–57; or (ii)
standard collection devices (questionnaires and stand-
ard operating procedures) may be suggested as a
required basis for collection of information.
49,58–61
It is with all of these considerations in mind that
the DataSHaPER project (DataSchema and
Harmonization Platform for Epidemiological
Research) has been launched. The DataSHaPER
(http://www.datashaper.org) offers free access to
questionnaires and core sets of variables that can be
used to support the development of data-collection
tools for emerging studies or to serve as a central
reference for harmonization between pre-existing stu-
dies. The DataSHaPER is an international project that
is being developed under the joint umbrellas of P
3G
(the Public Population Project in Genomics
50,62),
PHOEBE (Promoting Harmonization of Epidemio-
logical Biobanks in Europe
63) and CPT (Canadian
Partnership for Tomorrow
64), in collaboration with
more than 50 major studies from around the world.
This conceptual article describes the motivation,
aims and scientific foundation of the DataSHaPER
project.
Harmonization
Standardization is a sine qua non of information pool-
ing. However, scientific, technological, ethical, cul-
tural and other constraints make it difficult to
impose identical infrastructures and uniform proced-
ures across studies. Furthermore, it is important to
recognize that it is not always necessary to use pre-
cisely the same methods and tools for data collection
in order to achieve valid data integration across stu-
dies. Rather, what ‘is’ crucial is that the information
conveyed by each data set is ‘inferentially equivalent’.
If the ‘quality’ of the data to be integrated is also
adequate, inferential equivalence greatly increases
the potential for collaboration between studies and,
therefore, the scientific opportunities. The definition
of equivalence will vary with the scientific context
and must take into account both the primary infor-
mation collected (e.g. serum cholesterol level) and the
qualifying factors that can influence the interpretation
of that information (e.g. whether the participant had
been fasting prior to sample collection). In some situ-
ations, even a small change in the way information is
collected can substantially modify scientific compati-
bility, whereas in others, considerable flexibility can
be allowed. Formally, a valid balance must be struck
between the use of precisely uniform specifications
that render pooling straightforward (e.g. identical
questions asked under identical conditions), and the
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be appropriate and more realistic in a collaborative
context (e.g. similar questions, but asked by an inter-
viewer in one study and completed by the participant
in another).
In an ideal world, information would be ‘prospect-
ively harmonized’: emerging studies would make use,
where possible, of harmonized questionnaires and
standard operating procedures.
53,65 This enhances
the potential for future pooling but entails significant
challenges—ahead of time—in developing and agree-
ing to common assessment protocols. However, at the
same time, it is important to increase the utility of
existing studies by ‘retrospectively harmonizing’ data
that have already been collected, to optimize the
subset of information that may legitimately be
pooled.
30,53,65 Here, the quantity and quality of infor-
mation that can be pooled is limited by the hetero-
geneity intrinsic to the pre-existing differences in
study design and conduct.
The DataSHaPER
Concept
The DataSHaPER is both a scientific approach and a
practical tool. Originally, the plan had been to develop
a standardized questionnaire (or set of question-
naires) with the primary aim of facilitating prospect-
ive harmonization of future biobanks. But after some
months of work, it became clear that complete stand-
ardization was too restrictive and would be of limited
applicability to retrospective harmonization. This re-
sulted in a fundamental change of approach that led
to the piloting of the concept that is now known as
the DataSHaPER. In order to understand the
DataSHaPER, an important distinction must be
drawn between core ‘variables’—the primary units
of interest in a statistical analysis—and the specific
‘assessment items’ that are collected by individual
studies (e.g. questions in questionnaires). It is a
pre-defined set of ‘variables’ that serves as the refer-
ence for harmonization between studies. This ap-
proach provides an appropriate level of flexibility,
because a given variable may potentially be con-
structed using different assessment items in different
studies. It is important to note that this does not
imply a reduction in scientific rigour; the specific in-
formation collected by a given study can only be
viewed as harmonized to a particular DataSHaPER
variable if the assessment items in that study can
be used to generate a ‘valid’ equivalent to the required
variable. This entails a formal scientific evaluation
and validation process.
Structurally, the DataSHaPER is a dynamically
evolving entity that is built upon two primary
components: the DataSchema Platform and the
Harmonization Platform. The former incorporates
and documents sets of core variables. The latter
reflects a step-by-step approach that facilitates esti-
mation of the potential for harmonization and pooling
between studies for defined scientific purposes. The
web-based application was developed by the
DataSHaPER team with the support of experts in
ontologies and open-source software. It is written in
Java and uses open-source libraries (Spring
Framework, Hibernate, Google Web Toolkit, Sesame/
Elmo, etc.). The user interface makes extensive use of
Asynchronous JavaScript and XML (AJAX) technolo-
gies, which provide for enhanced usability. Wherever
possible, standard formats and ontologies are used.
Thus, key information bearing objects (e.g.
DataSchemas and component elements of the
Harmonization Platform) are stored using a recog-
nized ontological format
66 to facilitate exchange
with other applications. Where relevant, the Generic
DataSchema makes use of terms defined in the
National Cancer Institute Thesaurus ontology (pub-
lished on the National Center for Biomedical
Ontology BioPortal).
67
Access to the DataSHaPER application and content
is open and free (http://www.datashaper.org). The
public website presents the published DataSchemas
and offers links to their ontology files. However,
to access the DataSchemas under development
as well as the results generated by the pre-existing
Harmonization Platforms, users need to respond
to specific criteria, be authenticated by the
DataSHaPER Team and use a username and password.
DataSchema Platform
A DataSchema is a hierarchical structure composed of
variables nested within domains, themes and modules
(Figure 1). Each DataSchema on the Platform is made
up of variables that may be derived from: interview
administration; health and risk-factor questionnaires;
physical and cognitive measures; medical files; sam-
ple collection, handling, processing and banking;
biochemical measures, registries (e.g. databases con-
taining deaths, hospitalization episodes and environ-
mental variables) and others. Variables may be of
primary scientific interest in their own right or qual-
ifying factors that contribute to the interpretation of
other information of primary interest. A variable may
be complete in itself [e.g. current smoker (yes/no) or
measured weight] or it may derive from one or sev-
eral others (e.g. body mass index).
The DataSchema platform on the DataSHaPER web-
site contains a comprehensive description of available
schemas. Each may include: a list of variables with
their definitions and formats; links to relevant ontol-
ogies; and access to reference questions/question-
naires, indexes and operating procedures that have
been selected
58,68,69 or developed.
70 Where possible,
variables have been defined such that they can reli-
ably be constructed from standard questionnaires and
classifications (e.g. The International Physical Activity
Questionnaire for physical activity
58). Although a
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prospective and retrospective harmonization, it also
provides a guide to help emerging projects select suit-
able assessment items and sample collection tools,
even when data pooling is not planned.
The ‘Generic DataSchema’ is the first schema to
have been developed under the DataSHaPER project.
It is aimed at supporting the construction of
general-purpose baseline questionnaires for use in
large cohorts enrolling middle-aged participants. Its
construction was a collaborative effort involving in-
vestigators from more than 25 international cohorts
in 14 countries. Its structure and contents were deter-
mined at a series of international consensus work-
shops held over 2 years (2006–08) with iterative
rounds of comments and feedback between meetings.
The contents were chosen so as to provide a core
data set with broad international applicability.
Ethnic and cultural specificity was therefore
minimized and the schema was chosen so as to be
simple enough to encourage widespread use, yet com-
prehensive enough to support meaningful research.
Detailed selection criteria for individual variables are
listed in Box 1.
The Generic DataSchema contains 3 modules,
13 themes, 45 domains and more than 180 variables.
As an illustrative example of its content (Figure 1),
the theme ‘sociodemographic characteristics’ con-
tains the domain ‘household status’ (defined as a
social unit comprised of one or more individuals
living together in the same dwelling, all of whom
need not be related) which in turn includes three
variables: (i) ‘marital status (currently married; yes/
no)’; (ii) ‘living with a partner in a common house-
hold (yes/no)’; and (iii) ‘number of people who live
with the participant in the same household
(number)’.
Early versions of the Generic DataSchema were
used by several large population-based studies to
help create their data-collection tools. These included
the LifeLines
71 (The Netherlands) and LifeGene
72
(Sweden) Projects as well as the five cohorts in the
CPT Project
64 and the Canadian Longitudinal Study
on Aging.
73
Box 1 Criteria for selecting individual variables in the
Generic DataSchema
(i) The variable is of substantial relevance to genomic
or public health research.
(ii) The variable may potentially be used for a wide
range of research questions in a variety of
populations.
(iii) Each level of response to a categorical variable is
of high enough prevalence to ensure that suffi-
cient power can potentially be obtained.
(iv) The assessment items required to generate the
variable can be obtained in a valid way and reli-
ably be assessed, where possible using standard
questions and/or indexes.
(v) The assessment items required to generate the
variable can be collected in a manner that entails
no major burden to participants.
(vi) The assessment items required to generate the
variable can be collected at acceptable cost.
(vii) A variable may be selected if it is of primary inter-
est in its own right, is a qualifying variable that
modifies the interpretation of other variables, or is
viewed as being a potentially important confoun-
der, or indicator of potential bias.
A fundamental aim was to restrict the Generic
DataSchema to a limited number of variables identified
as key by consensus.
Figure 1 Hierarchical structure of the module, theme and variables related to the ‘household status’ domain in the Generic
DataSchema
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It is the Harmonization Platform that enables a
DataSchema to be used as a basis for harmonization
in a specific scientific context. It provides a rigorous
approach to a three-step process that entails: (i) the
development of rules providing a formal assessment
of the potential for each individual study to generate
each of the variables in the DataSchema; (ii) the ap-
plication of these rules to determine and tabulate the
ability of each study to generate each variable, thereby
identifying the information that ‘can’ be shared;
(iii) where a variable can be constructed by a given
study, the development and application of a process-
ing algorithm enabling that study to generate the
required variable in an appropriate form.
The compatibility of variables is formally assessed
on a three-level scale of matching quality: ‘complete’,
‘partial’ or ‘impossible’ (e.g. see Table 1). This process
is referred to as ‘pairing’. Rules generated for variable
pairing are context specific and will vary according to
each harmonization project. Rule creation and pairing
are both systematic processes based on protocols
involving iteration between domain experts, research
assistants and a validation panel. The whole proced-
ure is subject to appropriate quality assurance.
The first use of the Harmonization Platform was in
association with the Generic DataSchema. Pairing
rules were therefore developed for all the variables
in that schema. As an illustrative example, Table 2
details the rules created for the variable ‘Current
quantity of red wine consumed (number of glasses
of red wine/week)’. Using such pairing rules, the po-
tential to harmonize 50 large population-based studies
(each including at least 10000 healthy participants)
has now been explored for ‘all’ variables in the
DataSchema: additional studies joined the collabor-
ation to enable this formal evaluation to take place.
In combination, these 50 collaborating studies have
recruited or plan to recruit a total of approximately
5.4 million participants.
The detailed results of the full pairing analysis will
form the basis of a second paper to follow. For the
purposes of the present conceptual article, we will
therefore do no more than provide a brief illustration
of the nature of the results to be anticipated. For ex-
ample, using the specific variable considered in
Table 2 (‘Average number of glasses of red wine con-
sumed by the participant per week’), 7 (14%) of the
50 studies generated a complete match, 3 (6%) a par-
tial match and 38 (76%) an impossible match. In the
particular case being considered, therefore, informa-
tion from approximately 873 900 participants might
potentially be co-analysed for the variable of interest;
i.e. from those studies that provide a complete match.
In contrast, when the variable ‘Current quantity of
wine consumed’ was considered (with no specifica-
tion of red or white wine), 21 (42%) studies provided
a complete match (1.8 million participants). As an-
other example, when the variable ‘measured weight’
was investigated, 36 (72%) studies (3.6 million par-
ticipants) provided a complete match. According to
the pairing rules in this setting, in order that it
might be considered a ‘complete match’, the weight
of the participant had necessarily to be ‘measured’ at
least once by a trained nurse/interviewer with a
standard device. Where, weight was ‘reported’ by
the participant, it was viewed only as a ‘partial
match’.
However, in order to answer a real scientific ques-
tion, the pairing statuses of more than one variable
must usually be considered simultaneously. For ex-
ample, if harmonized information is required on
‘Current quantity of wine consumed’, ‘Body Mass
Index’ and ‘Current Tobacco Smoker’, a total of
12 studies provide a complete match for all three vari-
ables (approximately 1 million participants). At the
same time, additional issues must also be taken into
account. These include ethico-legal constraints on
access to data or samples, the compatibility of differ-
ent study designs and protocols, and the distribution
of missing data. Consideration of such issues is
fundamental to scientific rigour in using the
DataSHaPER.
Discussion
The DataSHaPER was originally launched under the
P
3G
50,62 and PHOEBE
63 initiatives in response to re-
quests from the members of both consortia for guide-
lines to support the construction of questionnaires to
facilitate prospective harmonization of large
population-based studies. But the overall focus
evolved, and rapidly subsumed the critical need for
tools to support retrospective synthesis of information
between existing/legacy studies. As the nascent pro-
ject progressed, it became clear that one of the pri-
mary needs of the scientific community was to have
access to comprehensive documentation of the poten-
tial to synthesize data across subgroup of studies. It
was also recognized that such documentation needed
Table 1 Example of pairing results for the variables under the domain ‘Individual history of diabetes’
Individual history of diabetes Study A Study B Study C Study D Study E
Occurrence of diabetes Complete Complete Complete Complete Complete
Type of diabetes Impossible Impossible Complete Partial Impossible
Onset of diabetes Partial Complete Complete Complete Impossible
1388 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYto include descriptions of the procedures used to col-
lect data and to target both generic and specialized
data collected by studies using various designs. The
network of the DataSHaPER collaborators has there-
fore extended over time and now includes, e.g., sci-
entists working in disease-oriented networks of
studies such as Genecure (chronic kidney diseases).
74
Clearly, the ongoing development of new
DataSchemas and Harmonization Platforms will re-
flect the interests and needs of the scientific teams
using and developing them. As illustrative examples,
future DataSHaPERs may focus on particular condi-
tions (e.g. stroke, type 2 diabetes), social and lifestyle
factors (e.g. nutrition, environmental pollutants),
or specific population subgroups (e.g. newborn,
elderly).
Documenting the potential to synthesize informa-
tion across studies is critical and should foster collab-
oration, but it is only a step in the process leading to
the final statistical analyses making use of synthe-
sized data sets. In its recent development, the struc-
ture and web interface of the DataSHaPER is thus
being consolidated in order to facilitate complemen-
tarity with other tools and approaches to harmoniza-
tion, data access, processing, pooling and analysis
(e.g. PhenX
49, dbGaP
36, DataSHIELD,
75 OBiBa
76 and
SAIL
77). It is the access to such integrated suites of
tools that will ultimately facilitate the generation of
new scientific discoveries using large-scale synthe-
sized data sets across networks of studies.
The question ‘What would constitute the ultimate
proof of success or failure of the DataSHaPER
Table 2 Pairing rules used for the variable ‘Current quantity of red wine consumed’ and specific questions
asked by exemplar studies
Current quantity of red wine consumed 
(http://www.datashaper.org/Datashaper.html#dataschemasTab$RELEASE$GENERIC_1$GENERIC_2$GENERIC_
14$GENERIC_55$GENERIC_266)
  Definition: average number of glasses of red wine consumed by the participant per week; Unit: glasses of red wine/week;  
Format: open; Type: integer 
Complete: the meaning and format of the question or questions 
of the questionnaire allow the construction of the variable as 
described (definition and format)
Rules specific to ‘Current quantity of red wine consumed’: 
￿ the number of drinks can be collected per day, week, month, 
etc; 
￿ the size (millilitre, ounces, etc.) of the glasses or drinks can be 
specified or not; 
￿ the information can be collected for the entire week or for 
specific periods covering the whole week (week-days and 
week-end; Monday to Sunday, etc); 
￿ the question must target the current consumption (over the past 
12 months or more contemporaneously).
Exemplar question: Study A  
In a typical week, how many 
glasses of red wine (6 ounces) do 
you drink per day? 
[___] Number of drinks per day 
Exemplar question: Study B 
In general, how many glasses of 
red wine do you drink per day over 
a week and weekend? 
Week:         [___] Number/day 
Weekend:   [___] Number/day 
Partial: the meaning and the format of the question or questions 
of the questionnaire could allow the construction of the variable 
as described, but with an unavoidable loss of information
Rules specific to ‘Current quantity of red wine consumed’: 
￿ partial if categories are used instead of continuous variables.
Exemplar question: Study C 
In a typical week, how many 
glasses of red wine do you drink 
per day? 
 1–3 
 4–6 
 7–9 
 10 or more
Impossible: there is no information or insufficient information in 
the questionnaire to allow the construction of the variable as 
described
Rules specific to ‘Current quantity of red wine consumed’: 
￿ impossible if only wine is mentioned without distinction 
between types of wine (red, white); 
￿ impossible if relevant information is collected only for the 
consumption in the past (before the past 12 months); 
￿ impossible if relevant information is collected at the same time 
for the current and the past consumption without distinction 
between the two.
Exemplar question: Study D 
In a typical week over the past
3  years, how many drinks of wine   
did you drink per day? 
[___] Number of drinks per day 
Exemplar question: Study E 
Over the last 12 months, how 
many glasses of beer, wine and/or 
spirits altogether did you usually 
drink? 
Total Number of glasses per day:  
 1   2   3   4   5   6  
 7   8   9    10 or more 
DataSHaPER APPROACH TO INTEGRATING DATA 1389approach’ needs to be addressed. Such proof will ne-
cessarily accumulate over time, and will involve two
fundamental elements: (i) ratification of the basic
DataSHaPER approach; and (ii) confirmation of the
quality of each individual DataSHaPER as they are
developed and/or extended. An important indication
of the former would be provided by the widespread
use of our tools. However, the ultimate proof of prin-
ciple will necessarily be based on the generation of
replicable scientific findings by researchers using the
approach. But, for such evidence to accumulate it will
be essential to assure the quality of each individual
DataSHaPER (see Box 2). Even if the fundamental
approach is sound, its success will depend critically
on how individual DataSHaPERs are constructed
and used. It seems likely that if consistency and
quality are to be assured in the global development
of the approach, it will be necessary for new
DataSHaPERs to be formally endorsed by a central
advisory team.
The novelty of the DataSHaPER is not in the scien-
tific challenges or solutions being addressed and pro-
posed: similar projects have been embarked upon
before. However, the DataSHaPER provides access to
useful tools (see Box 3) and has critical advantages.
The approach aims to be generic, flexible and can be
used both prospectively and retrospectively.
Furthermore, the web interface can easily be updated
as new DataSchema and Harmonization Platforms are
added and thus, provides a good potential for con-
stant improvement of the content. Finally, the
DataSHaPER has emerged as a common approach to
Box 2 Development of a DataSHaPER: how to ensure rigour of the process and formal validation of the outcomes
DataSchema
Process—the development of a DataSchema should be scientifically driven and based upon iterative review and con-
sensus methodologies.
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Outcome (list of core variables)—the structure and specific content of each schema has to be formally evaluated. This
involves, e.g., the assessment of the content by external groups of experts and systematic comparison with current
practice or relevant gold standards and guidelines. Furthermore, for the schemas underpinning data-collection devices
(e.g. questionnaires), formal validation of these resultant tools should be undertaken.
Harmonization Platform
Process—methodical quality control should be implemented through all of the harmonization process. This should
include systematic validation of the pairing rules that have been developed and analysis of the agreement between the
pairing classification achieved by different staff and an independent control panel.
Outcome (database including pairing results)—formal assessment of the impact of participant studies and variables char-
acteristics on the pairing results should be undertaken to define factors influencing the potential for synthesis. Factors
targeted include: (i) study characteristics such as design of the study (e.g. cohort or case–control study), nature of the
population (e.g. minimal age at recruitment, sex, place of residence) and the procedural methods used to collect
information (e.g. paper- or computer-based questionnaire); and (ii) variable characteristics such as whether the
variable has a quantitative or a categorical format, and whether the information defining a particular variable relates
to the participant or to his/her family.
Final set of synthesized ‘data’
As for any database generated by a stand-alone study, once it has been created, the final product of the harmon-
ization process (a synthesized database including data from all participating studies) should be subjected to standard
data validation procedures including appropriate range checking and tests of internal validity.
Box 3 Tools provided by the DataSHaPER (http://www.datashaper.org)
For emerging studies
– Lists of core variables useful in the development of information collection tools relevant in specific scientific
contexts.
– Exemplar questionnaires and standard operation procedures enabling collection of these core variables.
For network of studies to be prospectively or retrospectively harmonized
– A scientific method, web-based platform and provision of expertise for: (i) the definition of core set of variables to
be shared; and (ii) the development and application of the harmonization process.
1390 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYthe concrete need to document the potential to syn-
thesize data across biobanks and cohort studies.
However, the scientific utility of any synthesized
data set depends on the quality of data to be pooled
and on the rigour of the harmonization and synthesis
process. The DataSHaPER can make a valuable con-
tribution. However, if it is to be successful, it must
continue to evolve and it must be used both widely
and wisely.
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KEY MESSAGES
 Large-scale data pooling and meta-analysis are central to modern bioscience.
 If the data from two studies are sufficiently similar for a valid synthesized analysis, the two studies
may be said to be harmonized in the particular scientific context that applies.
 The DataSHaPER (DataSchema and Harmonization Platform for Epidemiological Research) provides a
flexible, but structured, approach to harmonization and data synthesis.
 A DataSchema provides a selected set of core variables to be shared between studies while the
Harmonization Platform contains rules that determine whether the particular data items collected
by a given study can be used to create each DataSchema variable.
 The DataSHaPER may be used prospectively, as a source of harmonized questions for new studies, or
retrospectively as a structured framework for harmonizing existing/legacy studies.
 Access to the DataSHaPER application and content is open and free through its public website at:
http://www.datashaper.org/. To access the Harmonization Platform (for retrospective harmonization),
users must register with the DataSHaPER Team.
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